Introduction
Over the past decade, major advances have been made in the fields of solid organ and stem cell transplantation [1] . Rejection, once the leading cause of graft failure and death, has been largely controlled thanks to more potent immunosuppressive medications. As a consequence, infections are emerging as the most significant causes of transplantation-associated morbidity and mortality [2] . Respiratory viral infections are increasingly recognized as a cause of morbidity, graft failure, and death in transplant recipients. Since the most recent review of respiratory viral infections in transplant recipients [3] , a number of studies have advanced our understanding of the importance of these respiratory viruses and our ability to manage them.
Epidemiology of respiratory viral infections
Few prospective studies of respiratory viral infections using contemporary diagnostic techniques in transplant recipients have been done, and most have been limited to stem cell and lung transplant recipients. As a result, the true incidence of respiratory viral infections in this population is not clearly known (Table 1) . Older studies likely underestimated the incidence and overestimated the severity of infections, because they often selected for patients who were sick enough for hospitalization and had evidence of lower tract disease.
Prior studies clearly demonstrate that respiratory viral infections circulate among transplant recipients during the same seasons as in the general population. Transplant recipients often have atypical presentations of respiratory infection [3] . Viral shedding tends to be prolonged in transplant recipients and may occur without significant symptoms; this increases the risk of antiviral resistance emergence during therapy [4,5 •• ]. Respiratory viral infections are associated with increased risk of death, development of viral pneumonia, and coinfections, particularly bacterial pneumonia and invasive aspergillosis [3, 6] . Last, respiratory viral infections are associated with acute and chronic rejection, particularly in lung transplant recipients [7 •• ].
Diagnosis of respiratory viral infections
A diagnosis of respiratory viruses can be made by culture, rapid antigen detection, polymerase chain reaction (PCR), or monoclonal antibody testing. Cultures tend to have low recovery and can take several days to several weeks to become positive [3] . Although rapid antigen tests are easy to perform and yield results within 15-30 minutes, they have low sensitivity in the transplant population [8-10, 11 •• ,12-16]. PCR, using either a commercially-available multiplex reverse transcription PCR enzyme hybridization assays (Hexaplex; sensitivity of 84-100% and specificity of 93%) [16, 17] 
Respiratory syncytial virus
The epidemiology and clinical presentation of respiratory syncytial virus (RSV) in transplant recipients has been well described elsewhere [3,4,23,24 • ,25-28]. Unfortunately, little progress has been made in the management of RSV in immunocompromised patients. Prevention is predominately through infection control methods [29, 30] [36] [37] [38] . Further studies are needed to determine whether one antibody preparation is superior (see Table 2 ); until then, combination therapy with any of the antibody preparations is the preferred therapeutic modality [3,39,40 • ].
Influenza
The epidemiology and clinical presentation of influenza have been extensively reviewed elsewhere [3,5,6,41]. Prolonged shedding is common, with resultant resistance emergence in a smaller number of transplant recipients [3,5,42 • ]. Allograft dysfunction and rejection, especially in lung transplant recipients, are recognized sequelae of influenza infection involving the lower respiratory tract [41] .
Prevention
Influenza can be prevented by immunization or by the use of antiviral agents. Prospective studies of annual influenza immunization have demonstrated safety but variable efficacy in transplant recipients [43] [44] [45] [46] . Response to vaccine is dependent on the type and degree of immunosuppression, as well as time since transplant, with a minimal response noted in HSCT recipients in the first 6-12 months after transplant [3] . Annual vaccination is recommended for all transplant recipients and their close contacts [47] .
The M2 and neuraminidase inhibitors have been documented to be safe and effective in preventing influenza 
Adenovirus
Adenovirus can cause a wide range of infections, particularly in the compromised host. The primarily affected organ is often related to the type of transplant: HSCT is most frequently associated with hemorrhagic cystitis, liver transplantation is most frequently associated with hepatic and gastrointestinal manifestations, and lung transplantation is most frequently associated with pulmonary involvement [3] . Although disease limited to a single organ can cause significant morbidity and rarely mortality, dissemination to other organs, particularly the lungs, portends an especially poor prognosis.
Retrospective data suggest that adenovirus occurs in approximately 29% of HSCT recipients and 1-10% of lung transplant recipients [3] . Two prospective studies found that adenovirus is a rare cause of symptomatic respiratory disease [20 •• ,21]. Emerging data suggest that adenoviremia may occur frequently after solid organ transplantation (7.2-22.5%) but is associated with few to no symptoms and recovery without sequelae
Adenoviremia is common but associated with significant illness and death in pediatric HSCT recipients. In one study, 42% of the children had adenoviremia develop, but only 7 of 11 cleared the virus successfully (see Table 4 )
In another study, adenoviremia was detected as part of routine screening in 6 pediatric transplant recipients (4 liver, 1 HSCT, 1 combined liver plus HSCT) [58] . None of the patients were symptomatic with their initial positive result, but all eventually became symptomatic, with 3 deaths despite cidofovir therapy [58] . These data suggest that, in asymptomatic solid organ recipients, detection of adenovirus in the blood is likely of minimal consequence. 
Ganciclovir
HSCT recipients who did not receive ganciclovir were at higher risk of adenoviral infections developing (odds Graft failure, interstitial pneumonitis and diarrhea (died) 7
Fever and skin rash 8 Hematuria 9
Gastroenteropathy 10 Hematuria 11
Reactive arthritis Adapted with permission [57].
ratio, 1.8) [64] . No difference was found in the frequency of adenoviremia in solid organ transplant recipients who received either oral valganciclovir versus ganciclovir, suggesting that ganciclovir is not effective in preventing adenoviremia in this population [56 •• ].
Ribavirin
In-vitro testing has demonstrated that ribavirin is only active against subgroup C viruses (serogroup 1, 2, 5, and 6) [65] . 
Cidofovir
Cidofovir has stronger evidence that it is active both in vitro and in vivo than do the other antivirals [65] . A variety of doses, including 5 mg/kg every 1-2 weeks and 1 mg/kg three times a week is associated with greater survival than treatment with other antivirals [3, 63, 67] .
For hemorrhagic cystitis without evidence of dissemination, cidofovir seems to reduce the degree of hemorrhage and clear the virus. The available literature documents 93% of patients treated with low-dose cidofovir (1 mg/kg/day, three times weekly for 3 weeks) cleared the adenovirus from their urine, and 79% had clinical improvements in hemorrhagic cystitis. Unfortunately, 50% had some degree of nephrotoxicity [68,69 • ]. One patient has also been successfully treated with intravesicular cidofovir (5 mg/kg diluted in 100 ml of saline instilled in the bladder twice per day) [70] .
The clearest evidence of cidofovir's efficacy comes from a study of 8 viremic HSCTrecipients who were treated with cidofovir (5 mg/kg every week for 2 weeks followed by 5 mg/kg every 10-14 days) and monitored with serial adenoviral load measurements. Five patients had clinical and virologic improvement. The others had progressive replication and death. Response to therapy was noted within the first week of therapy (1.4 log 10 reduction) among responders [ 
Treatment
Two antiviral agents, the capsid inhibitors pleconaril and the 3C protease inhibitors ruprintrivir (AG7088), have been studied in the treatment of picornavirus infection but are not clinically available for use [79, 80] .
Human metapneumovirus
The epidemiology and clinical presentation of the newly described human metapneumovirus (hMPV) has been extensively reviewed elsewhere [81 •• ,82,83]. hMPV requires PCR for diagnosis [82, [84] [85] [86] [87] [88] . Clinically, hMPV infections have a similar epidemiology and presentation to RSV in both immunocompetent and immunocompromised patients. The presence of other viral co-pathogens, particularly RSV, seems to predispose to lower respiratory tract disease and a more severe course [89, 90] . Although progression to respiratory failure and death has been reported in transplant recipients, the incidence of hMPV in these populations has not been prospectively studied [ No documented therapies, other than interferon, have been proven effective in management of coronavirus infections.
Conclusion
Respiratory viruses are common causes of respiratory tract infection associated with significant morbi tidy and mortality. Recent studies suggest that M2 and neuraminidase inhibitors, alone or in combination, result in shorter duration of viral replication, decreased progression to lower tract disease, and reduced mortality related to influenza. PIV is increasingly recognized as a strong risk factor for the development of acute and chronic rejection. Adenovirus is still a significant pathogen in HSCT recipients, and asymptomatic viremia occurs frequently in solid organ recipients. In-vitro and in-vivo studies suggest that cidofovir is the treatment of choice for significant adenoviral infections. Last, HRV, hMPV, and CoV, including SARS-CoV, are increasingly being recognized as significant pathogens in transplant recipients. Further studies to prospectively define the epidemiology and outcomes of these infections are essential as are studies of prophylactic and therapeutic modalities.
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as: A natural history study of respiratory syncytial virus (RSV) in hematopoietic stem cell transplant (HSCT) recipients; most of the recipients were getting an autologous HSCT for multiple myeloma. The authors concluded that it was safe to proceed with HSCT despite isolation of RSV. They also demonstrated a higher rate of hypoxemia (23% versus 10%), respiratory failure (4% versus 2%), and death (5% versus 2%) in infected patients.
••
32 Peck AJ, Corey L, Boeckh M. Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. Clin Infect Dis 2004; 39:673--680. A prospective study that documented delay of hematopoietic stem cell transplantation secondary to respiratory syncytial virus (RSV) infection had no effect on 1-year survival compared with patients who were not infected with RSV and thus did not have a delay. 
